TMS: Positive results with data to prove it
In trial after trial, the benefits reported by patients and doctors on NeuroStar TMS therapy show that NeuroStar is safe, effective, low-risk treatment for
Major Depressive Disorder (MDD). The compilation of these outcomes makes up the largest Outcome Registry2 in the world for any MDD treatment.
Meaning, NeuroStar is proven to be effective and safe—as shown by the clinical data of more than 65 studies.4
- The world’s largest Outcome Registry** in depression12
- Results in 30 publications
- Two randomized, controlled trials
- One large real-world trial
- 12-month durability data5,8
With TMS Long-lasting Symptom Relief and Remission are Possible.5,8
Clinical studies also showed a low discontinuation rate of only 5%.9,10
**Outcomes Registry data was published by Sackeim HA, et al. J Affective Disorders, 2020, 277(12):65-74. The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score <=3 and “complete remission” was defined as a CGI-S score <=2 at the end of treatment.